RT Journal Article
T1 Rationale and design of DiPPI: A randomized controlled trial to evaluate the safety and effectiveness of progressive hemodialysis in incident patients.
T2 Justificación y diseño de DiPPI: un ensayo controlado aleatorizado para evaluar la seguridad y la efectividad de la hemodiálisis progresiva en pacientes incidentes.
A1 Suárez, Miguel A
A1 García-Cabrera, Emilio
A1 Gascón, Antonio
A1 López, Francisca
A1 Torregrosa, Eduardo
A1 García, Giannina E
A1 Huertas, Jorge
A1 de la Flor, José C
A1 Puello, Suleyka
A1 Gómez-Raja, Jonathan
A1 Grande, Jesús
A1 Lerma, José L
A1 Corradino, Carlos
A1 Ramos, Manuel
A1 Martín, Jesús
A1 Basile, Carlo
A1 Casino, Francesco G
A1 Deira, Javier
K1 Chronic renal failure
K1 Estudio aleatorizado controlado
K1 Hemodiálisis incremental
K1 Hemodiálisis progresiva
K1 Incremental haemodialysis
K1 Insuficiencia renal crónica
K1 Progressive haemodialysis
K1 Randomized clinical trial
AB Progressive haemodialysis (HD) is a starting regime for renal replacement therapy (RRT) adapted to each patient's necessities. It is mainly conditioned by the residual renal function (RRF). The frequency of sessions with which patients start HD (one or two sessions per week), is lower than that for conventional HD (three times per week). Such frequency is increased (from one to two sessions, and from two to three sessions) as the RRF declines. IHDIP is a multicentre randomised experimental open trial. It is randomised in a 1:1 ratio and controlled through usual clinical practice, with a low intervention level and non-commercial. It includes 152 patients older than 18 years with chronic renal disease stage 5 and start HD as RRT, with an RRF of ≥4ml/min/1.73m2, measured by renal clearance of urea (KrU). The intervention group includes 76 patients who will start with one session of HD per week (progressive HD). The control group includes 76 patients who will start with three sessions per week (conventional HD). The primary purpose is assessing the survival rate, while the secondary purposes are the morbidity rate (hospital admissions), the clinical parameters, the quality of life and the efficiency. This study will enable us to know, with the highest level of scientific evidence, the number of sessions a patient should receive when starting the HD treatment, depending on his/her RRF. Registered at the U.S. National Institutes of Health, ClinicalTrials.gov under the number NCT03239808.
YR 2018
FD 2018-10-19
LK http://hdl.handle.net/10668/13111
UL http://hdl.handle.net/10668/13111
LA en
LA es
DS RISalud
RD Apr 12, 2025